Medication
Jamp Guanfacine XR
DIN 02523566 · Jamp Pharma Corporation Likely a generic
What it is
- Active ingredients
- Guanfacine — 2 mg
- Form and route
- Tablet (Extended-Release) · Oral
- Schedule
- PRESCRIPTION
- Authorised since
- 2022-01-26
Source: Health Canada — Drug Product Database. Data current as of 2026-08-12.
Products with the same active ingredient
Grouped by Health Canada’s active-ingredient group number. Products in a group do not always share a strength — check the strength above against your own. Sharing an active ingredient does not mean two products can be substituted for each other: whether a substitution is permitted is a provincial decision, and this page does not show it. Ask a pharmacist.
Watch this medication
Ontario Drug Benefit coverage
As of 31 July 2026Limited Use benefit Part XII
Ontario lists this product as a Limited Use benefit — Part XII of the Formulary/CDI. ODB pays for it only in the specific circumstances Ontario sets out against it, and the prescription has to carry a Limited Use code from the prescriber.
The criteria are set by Ontario and are not reproduced here — they are a matter for the prescriber.
- What ODB pays per unit
- $0.9353
This is what the Ontario Drug Benefit program reimburses a pharmacy for one unit, as of 31 July 2026. A deductible and a co-payment sit on top of it and differ by program — ODB, the Trillium Drug Program and the seniors co-payment each work differently — so it is not the figure anyone is charged at a counter. It also says nothing about private, workplace or federal coverage.
Source: Ontario Ministry of Health — ODB Formulary. Data current as of 2026-07-28. Ontario only. Formulary edition 4342, effective 31 July 2026.
Products Ontario considers interchangeable
As of 31 July 2026Ontario groups these products together at 2mg ER Tab and will substitute one for another at a pharmacy counter in Ontario.
- Apo-Guanfacine XR 02523736Apotex Inc
- Intuniv XR 02409119Takeda Canada Inc
- Sandoz Guanfacine XR 02563193Sandoz Canada Incorporated
This is Ontario’s designation, under the Ontario Drug Benefit program, and it applies in Ontario. It is a different statement from the same-active-ingredient list above, which is Health Canada’s grouping and carries no substitution meaning at all. No other province’s rules are shown on this page, and a designation here is not a recommendation to switch — that is a conversation with a pharmacist or prescriber.
Source: Ontario Ministry of Health — ODB Formulary. Data current as of 2026-07-28. Ontario only. Formulary edition 4342, effective 31 July 2026.
How it is classified
- Anatomical main group
- Cardiovascular system
- ATC code
- C02AC02
The Anatomical Therapeutic Chemical code records the body system a medicine acts on and its chemical grouping. It is not a statement of what this medication treats, and nothing on this page is. For the full classification of C02AC02, see the WHO ATC/DDD Index.
Recalls and safety alerts
As of 12 August 2026Health Canada has published 2 recalls or safety alerts naming this product. Read them on Health Canada’s own site, and speak to a pharmacist before changing anything about how you take this medication.
JAMP-Guanfacine XR 4 mg: Foreign matter
Health Canada says: Check your or your child's pill bottle to ensure that the green JAMP Guanfacine XR 4mg tablets do not have any brown or amber-coloured stains. If stains are identified, or if you are unsure, return it to your pharmacy for a replacement.Talk to a health care professional if you have questions or have health concerns.Contact JAMP Pharma Corporation by calling 450-449-4326 (option 3) or 1-866-399-9091 (option 3), or by email at custjamp@jamppharma.com if you have questions about this recall.Report any health product-related side effects or complaints to Health Canada.Additional information for health professionals:Health care professionals, such as pharmacists, should check bottles of Guanfacine XR 4 mg tablets before dispensing and report any unusual tablets or other issue to the company and to Health Canada.
Matched on the product name at the start of the notice.
JAMP Guanfacine XR 1 mg: Foreign tablets
Health Canada says: Check your or your child's pill bottle of JAMP Guanfacine XR 1 mg tablets to ensure it contains only 1 mg white, round tablets. If it contains any JAMP Guanfacine XR 4 mg green, oval tablets, or if you are unsure, return it to your pharmacy. Your pharmacist will check it and provide you with a replacement if needed.Contact a health care professional immediately if you or your child are experiencing signs and symptoms of overdose.Contact JAMP Pharma Corporation by calling toll-free at 1-866-399-9091, extension 501, or by email at custjamp@jamppharma.com, if you have questions about this recall.Report any health product-related side effects or complaints to Health Canada.Additional information for health professionals:Health care professionals, such as pharmacists, should check bottles of Guanfacine XR 1 mg tablets before dispensing and report any unusual bottles or other issue to the company and to Health Canada.
Matched on the product name at the start of the notice.
This list may be incomplete. Health Canada’s recalls data carries no DIN, so notices are matched on wording alone. Search Health Canada recalls for Jamp Guanfacine XR → How RxMonitor matches recalls, and how often it fails
Source: Health Canada — Recalls and Safety Alerts. Data current as of 2026-08-12. Matched on product name, not on DIN — the feed carries none.